[go: up one dir, main page]

TW200306206A - The use of histamine H4 receptor antagonist for the treatment of inflammatory responses - Google Patents

The use of histamine H4 receptor antagonist for the treatment of inflammatory responses Download PDF

Info

Publication number
TW200306206A
TW200306206A TW091136902A TW91136902A TW200306206A TW 200306206 A TW200306206 A TW 200306206A TW 091136902 A TW091136902 A TW 091136902A TW 91136902 A TW91136902 A TW 91136902A TW 200306206 A TW200306206 A TW 200306206A
Authority
TW
Taiwan
Prior art keywords
histamine
receptor
compound
patent application
scope
Prior art date
Application number
TW091136902A
Other languages
English (en)
Chinese (zh)
Inventor
Robin Thurmond
Siquan Sun
Lars Karlsson
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of TW200306206A publication Critical patent/TW200306206A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW091136902A 2001-12-21 2002-12-20 The use of histamine H4 receptor antagonist for the treatment of inflammatory responses TW200306206A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/036,648 US20030133931A1 (en) 2001-12-21 2001-12-21 Use of histamine H4 receptor antagonist for the treatment of inflammatory responses

Publications (1)

Publication Number Publication Date
TW200306206A true TW200306206A (en) 2003-11-16

Family

ID=21889815

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091136902A TW200306206A (en) 2001-12-21 2002-12-20 The use of histamine H4 receptor antagonist for the treatment of inflammatory responses

Country Status (8)

Country Link
US (1) US20030133931A1 (fr)
EP (1) EP1458885A2 (fr)
JP (1) JP2005539207A (fr)
AR (1) AR037975A1 (fr)
AU (1) AU2002348265A1 (fr)
CA (1) CA2471214A1 (fr)
TW (1) TW200306206A (fr)
WO (1) WO2003057919A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127395A1 (en) * 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
CA2497788A1 (fr) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Utilisation de modulateurs du recepteur h4 de l'histamine pour le traitement des allergies et de l'asthme
US20080102476A1 (en) * 2003-09-26 2008-05-01 Lars Karlsson Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546407B1 (fr) * 1983-05-24 1986-04-18 Therapeutique Applic Sa Medicament a activite anti-allergique pour administration locale a base d'acide n-acetyl(a,b)-aspartyl glutamique
WO2001085786A2 (fr) * 2000-05-05 2001-11-15 Wyeth Recepteur a l'histamine h4 humain
GB0101223D0 (en) * 2001-01-17 2001-02-28 Pfizer Ltd Histamine receptor antagonists

Also Published As

Publication number Publication date
AU2002348265A1 (en) 2003-07-24
EP1458885A2 (fr) 2004-09-22
US20030133931A1 (en) 2003-07-17
WO2003057919A3 (fr) 2003-10-30
JP2005539207A (ja) 2005-12-22
WO2003057919A2 (fr) 2003-07-17
CA2471214A1 (fr) 2003-07-17
AR037975A1 (es) 2004-12-22

Similar Documents

Publication Publication Date Title
EP3555122B1 (fr) Récepteur de cytokine leurre
JP2000503521A (ja) 末梢神経系特異的ナトリウムチャンネル、それをコードするｄｎａ、結晶化、ｘ線回折、コンピューター分子モデリング、合理的薬物設計、薬物スクリーニング、ならびにその製造法および使用法
US20040105856A1 (en) Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
TW200306206A (en) The use of histamine H4 receptor antagonist for the treatment of inflammatory responses
KR20010081109A (ko) 신규 ｇ 단백질 공액형 리셉터단백질, 그 ｄｎａ 및 그리간드
CN101300346A (zh) 新型生理物质nesfatin及其相关物质、以及它们的用途
US7662574B2 (en) Use of a G protein-coupled receptor and its cognizant ligand in the identification of compounds that affect prolactin secretion
JP2002345468A (ja) 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ
JPH10512154A (ja) 膵臓で発現する新規なケモカイン
US7235531B2 (en) Tachykinin-like polypeptides and use thereof
JP4188720B2 (ja) 新規スクリーニング方法
EP1880730A1 (fr) Fonctions et utilisation du gene gpr39 dans le systeme nerveux central des mammiferes
JP4184697B2 (ja) スクリーニング方法
JP2000078994A (ja) 新規７―トランスメンブラン受容体をコ―ドしているｃＤＮＡクロ―ンＨＮＦＤＹ２０
JP4574177B2 (ja) 新規スクリーニング方法
US20050159355A1 (en) Novel leukotriene, B4 receptor
EP1945661B1 (fr) Récepteur gpr 146
US20030078218A1 (en) Inflammation related G-protein coupled receptor
WO2005121356A1 (fr) Nouveau procédé de recherche par criblage
EP1627051A2 (fr) Regulation de l'expression d'acheron
JP4676608B2 (ja) 新規タヒキニン様ポリペプチドおよびその用途
EP1602380A1 (fr) Substance preventive/therapeutique pour les maladies de l'appareil digestif superieur
WO2005033700A1 (fr) Methode de criblage d'un agent ameliorant la resistance a l'insuline
WO2003072780A1 (fr) Nouvelles protéines, leurs adn et leur utilisation
US20050233304A1 (en) Method of screening remedy for renal failure